Head to Head Survey: Biodesix (NASDAQ:BDSX) & Personalis (NASDAQ:PSNL)

Biodesix (NASDAQ:BDSXGet Free Report) and Personalis (NASDAQ:PSNLGet Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Institutional and Insider Ownership

21.0% of Biodesix shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 63.8% of Biodesix shares are held by company insiders. Comparatively, 4.1% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Biodesix and Personalis, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biodesix 0 0 3 0 3.00
Personalis 0 0 2 0 3.00

Biodesix currently has a consensus target price of $3.50, indicating a potential upside of 173.44%. Personalis has a consensus target price of $5.50, indicating a potential upside of 298.55%. Given Personalis’ higher possible upside, analysts clearly believe Personalis is more favorable than Biodesix.


This table compares Biodesix and Personalis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biodesix -106.23% -29,379.44% -58.96%
Personalis -147.38% -61.42% -41.05%

Valuation & Earnings

This table compares Biodesix and Personalis’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biodesix $49.09 million 2.53 -$52.15 million ($0.65) -1.97
Personalis $73.48 million 0.95 -$108.30 million ($2.25) -0.61

Biodesix has higher earnings, but lower revenue than Personalis. Biodesix is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Biodesix has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.


Personalis beats Biodesix on 7 of the 13 factors compared between the two stocks.

About Biodesix

(Get Free Report)

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

About Personalis

(Get Free Report)

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.